Q2 EPS Forecast for Castle Biosciences Reduced by Analyst

Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Stock analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Castle Biosciences in a research report issued to clients and investors on Monday, July 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.51) per share for the quarter, down from their previous forecast of ($0.44). The consensus estimate for Castle Biosciences' current full-year earnings is $0.44 per share. Leerink Partnrs also issued estimates for Castle Biosciences' Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($1.92) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.55) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($2.05) EPS.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.12). The company had revenue of $87.99 million for the quarter, compared to analysts' expectations of $80.40 million. Castle Biosciences had a negative net margin of 1.46% and a positive return on equity of 3.41%.

Several other brokerages have also recently weighed in on CSTL. Guggenheim set a $30.00 target price on Castle Biosciences and gave the company a "buy" rating in a report on Friday, March 28th. Scotiabank dropped their price objective on Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating for the company in a report on Wednesday, May 21st. Canaccord Genuity Group dropped their price objective on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Lake Street Capital dropped their price objective on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences presently has a consensus rating of "Buy" and a consensus price target of $37.00.

Castle Biosciences Trading Down 2.2%

CSTL stock traded down $0.36 during trading on Wednesday, hitting $16.07. 288,409 shares of the company traded hands, compared to its average volume of 409,083. The firm has a market capitalization of $463.97 million, a PE ratio of -84.58 and a beta of 1.10. Castle Biosciences has a 1 year low of $15.45 and a 1 year high of $35.84. The company has a 50-day moving average of $18.06 and a 200-day moving average of $21.02. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.19 and a current ratio of 9.37.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CSTL. Covestor Ltd bought a new position in Castle Biosciences during the 4th quarter valued at approximately $25,000. Harbour Investments Inc. bought a new position in Castle Biosciences during the 1st quarter valued at approximately $50,000. Jones Financial Companies Lllp increased its position in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company's stock valued at $54,000 after buying an additional 2,648 shares in the last quarter. Amundi increased its position in Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company's stock valued at $79,000 after buying an additional 4,111 shares in the last quarter. Finally, CWM LLC increased its position in Castle Biosciences by 835.0% during the 1st quarter. CWM LLC now owns 4,142 shares of the company's stock valued at $83,000 after buying an additional 3,699 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.